Dec 9, 2024 · Adstiladrin is a prescription gene therapy used for the treatment of a certain type of bladder cancer. Adstiladrin contains nadofaragene firadenovec-vncg, a non-replicating …

ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non …

Clinical overview Indication: ADSTILADRIN® (nadofaragene firadenovec-vncg) is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients …

Sep 12, 2023 · ADSTILADRIN ® (nadofaragene firadenovec-vncg) is the first and only FDA-approved intravesical gene therapy for the treatment of adult patients with high-risk Bacillus …

Nadofaragene firadenovec uses a recombinant adenovirus that encodes for interferon alpha-2b gene. Intravesical instillation of interferon alone for bladder cancer produced complete …

ADSTILADRIN® is indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in …

FDA D.I.S.C.O. Burst Edition: FDA approval of Adstiladrin (nadofaragene firadenovec-vncg) for patients with high-risk Bacillus Calmette-Gu√©rin unresponsive non-muscle invasive bladder …

Apr 1, 2025 · Abstract On December 16, 2022, the FDA approved the adenoviral vector-based gene therapy nadofaragene firadenovec-vncg (brand name Adstiladrin) for the treatment of …

Nov 12, 2025 · Gene therapy works by delivering helpful genetic material directly into the bladder to fight cancer cells and boost the body’s immune response. Three gene therapies (nado …

Nadofaragene firadenovec-vncg is approved to treat: Non-muscle–invasive bladder cancer with carcinoma in situ. It is used in adults whose cancer does not respond to treatment with bacillus …